Precision-based immuno-molecular augmentation (PBIMA) computerized system, method, and therapeutic vaccine
AssigneeNeo7Bioscience, Inc.
InventorsShamsuddin Sultan Khan, John A. Catanzaro, Anton Yuryev
Life of this patent
Estimating the term…
Loading patent…
AssigneeNeo7Bioscience, Inc.
InventorsShamsuddin Sultan Khan, John A. Catanzaro, Anton Yuryev
Estimating the term…
As disclosed herein a precision based immunomolecular augmentation (PBIMA) high specificity patient profiling networked computer system, rapid therapeutic vaccine design method, and personalized vaccine, which utilizes immuno-molecular biopathway HLA affinity mapping and selection prediction ranking tools. This PBIMA approach comprises: Strategic-Selection, Molecular-Mapping, Antigen-Alignment, Receptor-Recognition, and Tactical Technology (SMART). The platform obtains data from a patient's genes and proteins as input. NGS data, including WES, WGS, ctDNA and cfDNA, RNAseq uses as input. PBIMA comprises a gene-protein-cell Cloud-based sequence editing interface to select the high confidence peptides. The PBIMA vaccine is a solution-based multi-purpose vaccine design strategy. PBIMA technology can produce therapeutic vaccines for cancer, autoimmune, neurodegenerative, inflammation-driven disease, and novel pathogen infection treatment. PBIMA therapeutic design is multi-mechanistic and broad-spectrum.
A precision-based immunomolecular augmentation (PBIMA) computerized method for designing and treating a patient with customized therapeutic peptides or peptide vaccine, comprising:
A precision-based immunomolecular augmentation (PBIMA) apparatus for designing and treating a patient with customized therapeutic peptides or peptide vaccine, comprising:
Dependencies are inferred from the claim text.